ReviewFrontiers in immunology2019
Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- The CXCL13 hub in obesity-related metabolic inflammation: regulation of spatiotemporal heterogeneity and targeted strategies.The Journal of endocrinology · 2026Review
- FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers.Scientific reports · 2025Article
- A novel prognostic model for lung squamous cell carcinoma based on multi-omics analysis and machine learning.PloS one · 2025Article
- The causal relationship between anti-CD20 antibodies and endometrial cancer: a Mendelian randomization study.Discover oncology · 2024Article
- Targeting signaling pathways with andrographolide in cancer therapy (Review).Molecular and clinical oncology · 2024Review
- Tertiary lymphoid structures and their therapeutic implications in cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Review
- Involvement of Intestinal Epithelium Aryl Hydrocarbon Receptor Expression and 3, 3'-Diindolylmethane in Colonic Tertiary Lymphoid Tissue Formation.International journal of molecular sciences · 2024Article
- Aryl hydrocarbon receptor activity in intestinal epithelial cells in the formation of colonic tertiary lymphoid tissues.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Lymphotoxin β receptor and tertiary lymphoid organs shape acute and chronic allograft rejection.JCI insight · 2024Article
- Article
- T Cell Development and Function.Rejuvenation research · 2023Review
- Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.Journal of nanobiotechnology · 2023Review
- Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?Pharmaceutics · 2022Review
- Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?Cells · 2022Review
- A B-cell or a key player? The different roles of B-cells and antibodies in melanoma.Pigment cell & melanoma research · 2022Review
- Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers · 2022Review
- NF-kB pathway is involved in microscopic colitis pathogenesis.The Journal of international medical research · 2022Article
- Control of Dendritic Cell Function Within the Tumour Microenvironment.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system plays pivotal roles in the occurrence and progression of cancers. As blockade of immune-checkpoint has been proven effective at improving anti-tumor immune response in multiple tumor types, the tumor immunotherapy still faces many challenges. Emerging evidence indicates lymphoid organ-like structures, also called tertiary lymphoid organs (TLOs) or ectopic lymphoid organs (ELOs), have been identified in cancers, as the result of lymphoid neoorganogenesis. The prognostic value of TLOs in cancer patients has been evaluated with debates, however, such well-organized lymphoid structures in the site of cancer indicate TLOs are the important modulators of cancer immunological microenvironment. TLOs have attracted remarkable efforts to investigate their neoorganogenesis and function in immune responses, aiming to develop new strategies for cancer immunotherapy. In this review, we summarize the current understandings about the molecular and cellular mechanisms governing the formation and function of TLOs in immune responses against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.